Prurigo Nodularis
Conditions
Interventions
Trial group:Dupilumab subcutaneous injection and Ku Qin Formula orally
Control group:Dupilumab subcutaneous injection
Sponsors
Yueyang Hospital of Integrative Medicine, Shanghai University of Traditional Chinese Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 85 Years
Inclusion criteria
Inclusion criteria: (1) Determined to meet the diagnostic criteria of Western medicine and traditional Chinese medicine regarding Prurigo Nodularis and conform to the pattern of dampness-heat-wind-toxicity; (2) Age 18-85 years old, gender is not limited; (3) No treatment related to Prurigo Nodularis within 2 weeks before enrollment; (4) Signed informed consent.
Exclusion criteria
Exclusion criteria: (1) Patients who have participated or are currently participating in other clinical trials within the last 1 month; (2) Persons with acute infectious diseases or infections; (3) Women who are in preparation for pregnancy, pregnancy, or breastfeeding; (4) Patients with severe cardiovascular, cerebrovascular, hepatic, renal and hematopoietic system primary diseases, or psychiatric disorders; (5) Known hypersensitivity to the medication used in this treatment and intolerance to the treatment method.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Pruritus relief rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Skin lesion severity score;time to recurrence;the Dermatology Life Quality Index;Chinese Medicine Symptom Score; | — |
Countries
China
Contacts
Public ContactWang Yifei
Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine
Outcome results
None listed